key: cord-0743319-jaiyqh8p
authors: Piccoli, Luca; Park, Young-Jun; Tortorici, M. Alejandra; Czudnochowski, Nadine; Walls, Alexandra C.; Beltramello, Martina; Silacci-Fregni, Chiara; Pinto, Dora; Rosen, Laura E.; Bowen, John E.; Acton, Oliver J.; Jaconi, Stefano; Guarino, Barbara; Minola, Andrea; Zatta, Fabrizia; Sprugasci, Nicole; Bassi, Jessica; Peter, Alessia; De Marco, Anna; Nix, Jay C.; Mele, Federico; Jovic, Sandra; Rodriguez, Blanca Fernandez; Gupta, Sneha V.; Jin, Feng; Piumatti, Giovanni; Lo Presti, Giorgia; Pellanda, Alessandra Franzetti; Biggiogero, Maira; Tarkowski, Maciej; Pizzuto, Matteo S.; Cameroni, Elisabetta; Havenar-Daughton, Colin; Smithey, Megan; Hong, David; Lepori, Valentino; Albanese, Emiliano; Ceschi, Alessandro; Bernasconi, Enos; Elzi, Luigia; Ferrari, Paolo; Garzoni, Christian; Riva, Agostino; Snell, Gyorgy; Sallusto, Federica; Fink, Katja; Virgin, Herbert W.; Lanzavecchia, Antonio; Corti, Davide; Veesler, David
title: Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology
date: 2020-09-16
journal: Cell
DOI: 10.1016/j.cell.2020.09.037
sha: 46770bb9e57d10158e1e43dfd0a7591d56364d58
doc_id: 743319
cord_uid: jaiyqh8p

Analysis of the specificity and kinetics of neutralizing antibodies (nAbs) elicited by SARS-CoV-2 infection is crucial for understanding immune protection and identifying targets for vaccine design. In a cohort of 647 SARS-CoV-2-infected subjects we found that both the magnitude of Ab responses to SARS-CoV-2 spike (S) and nucleoprotein and nAb titers correlate with clinical scores. The receptor-binding domain (RBD) is immunodominant and the target of 90% of the neutralizing activity present in SARS-CoV-2 immune sera. Whereas overall RBD-specific serum IgG titers waned with a half-life of 49 days, nAb titers and avidity increased over time for some individuals, consistent with affinity maturation. We structurally defined an RBD antigenic map and serologically quantified serum Abs specific for distinct RBD epitopes leading to the identification of two major receptor-binding motif antigenic sites. Our results explain the immunodominance of the receptor-binding motif and will guide the design of COVID-19 vaccines and therapeutics.

Prophylactic or therapeutic use of neutralizing mAbs could thus help control SARS-CoV-143 2 transmission by providing immediate protection. We recently described the mAb 144 S309, which was isolated from the memory B cells of a SARS survivor (10 years after 145 infection) and neutralized both SARS-CoV and SARS-CoV-2 by recognizing a 146

conserved RBD epitope (Pinto et al., 2020) . Furthermore, recent reports have described natural SARS-CoV-2 infection remain largely elusive. 153 We describe here the specificity and kinetics of Ab responses to the SARS-CoV-154 2 N and S proteins based on analysis of 647 plasma and serum samples from 155

hospitalized, symptomatic and asymptomatic COVID-19 patients. Hospitalized 156

individuals developed higher titers of serum IgG and detectable levels of IgA, compared 157 to non-hospitalized or asymptomatic subjects in which we observed a highly 158 heterogeneous response. We found that more than 90% of the SARS-CoV-2 159 neutralizing humoral responses are accounted for by RBD-directed Abs and obtained a 160 map of the major RBD antigenic sites through structural studies of mAbs derived from 161 SARS-CoV-2 and SARS-CoV immune donors. Development of an RBD blockade-of-162

binding assay enabled quantitative evaluation of Ab responses against each RBD 163 antigenic site in SARS-CoV-2-exposed individuals and identified two sites targeted by 164 most serum Abs. These results provide a structural framework to understand the 165 humoral immune response against SARS-CoV-2 and will guide future serology studies 166 as well as vaccine and therapeutic design strategies. 167 168 RESULTS 169

The IgG, IgA and IgM response to SARS-CoV-2 infection 170 We analyzed plasma or serum samples collected between March and July 2020 171 from 647 SARS-CoV-2-infected individuals, as determined by PCR (n=271) or by 172 diagnosis based on signs and symptoms (n=376). A total of 1,078 samples, including 173 multiple time points, were collected from 5 different cohorts in Italy, Switzerland and the 174 US, which comprised 47 hospitalized, 556 symptomatic and 44 asymptomatic 175 individuals, as well as 32 pre-pandemic healthy donors (Figure S1A-C) . For each 176 sample, we evaluated IgG, IgA and IgM binding titers to the SARS-CoV-2 prefusion-177 stabilized S ectodomain trimer (Walls et al., 2020) , the RBD, domain A (residues 14-178 302), the S 2 subunit (residues 685-1211) and the N protein by ELISA. 179

The IgG responses were on average 1-2 orders of magnitude higher in 180 hospitalized relative to non-hospitalized individuals and varied across SARS-CoV-2 181 antigens and among subjects (Figures 1A and S2A ; Data S1). Males had higher Ab 182 titers than females, although no correlation with age was observed (Data S2). Levels of 183 SARS-CoV-2 S-and N-specific IgG correlated within each individual (p value <0.0001) 184

( Figure S2D ). SARS-CoV-2 RBD-specific Abs dominated IgG responses whereas much 185 lower titers were observed to the S 2 subunit or domain A ( Figure 1A) . These findings 186 might be related to the more extensive N-glycan shielding of domain A and the S 2 187 subunit, which respectively harbor 8 and 9 oligosaccharides, relative to the RBD that 188

only possesses 2 N-linked glycans (Walls et al., 2020; Watanabe et al., 2020) . We also 189

found that the majority of samples contained IgG cross-reactive to the SARS-CoV 190

prefusion-stabilized S ectodomain (Walls et al., 2019) and RBD with 3-fold and 15-fold 191 lower binding titers than those for the corresponding SARS-CoV-2 antigens, 192 respectively ( Figure S2E -G). The observed Ab cross-reactivity between these two 193 viruses are consistent with the 76% sequence identity shared between the two S 194 glycoprotein ectodomains and recent findings (Barnes et al., 2020) .

IgA responses to SARS-CoV-2 S and N were detected almost exclusively in 196 hospitalized patients (Figures 1B and S2B ; Data S1 and S2) whereas IgM responses 197

were limited to S and undetectable for N (Figures 1C and S2C ; Data S1 and S2). In 198 addition, we observed that SARS-CoV-2 S-and RBD-specific IgM were detectable up to 199 60 days after symptom onset, suggesting that detection of IgM antibodies is not 200 associated with an ongoing or recent infection ( Figure S2C ). Finally, in the 459 201

individuals of the Ticino healthcare workers cohort, for which a symptom score was 202 available, we observed that SARS-CoV-2 RBD-specific IgG, IgA and IgM and SARS-203

CoV-2 N-specific IgG binding titers were proportional to the severity of symptoms 204

( Figure 1D and Data S2). This serological analysis indicates that Ab responses varied 205 amongst different individuals and amongst groups, with binding titers proportional to the 206 severity of symptoms, possibly due to a prolonged exposure to large amounts of viral 207

antigens during the course of viral disease. 208 209

We next determined if the RBD is the primary target of neutralizing Abs in 211 COVID-19 convalescent plasma by measuring neutralizing titers before and after Ab 212 depletion using RBD-coated beads. We found that an almost complete depletion of 213 RBD-specific Abs from 21 plasma samples reduced SARS-CoV-2 neutralizing titers by 214 ~90% on average ( Figure 1E and Data S2). We then evaluated whether RBD-specific 215

Abs in patient serum or plasma samples inhibit binding of the SARS-CoV-2 RBD to 216

ACE2. Although 77% of hospitalized individuals had Ab titers that blocked SARS-CoV-2 217 RBD binding to ACE2 efficiently (BD80 > 10), only 18% and 11% of non-hospitalized 218 symptomatic and asymptomatic individuals had Abs strongly interfering with ACE2 219 J o u r n a l P r e -p r o o f binding, respectively ( Figure 1F ). The proportion of non-hospitalized individuals with 220 ACE2-blocking Abs correlated with the anti-RBD Ab binding titers which parallel 221 symptom severity (Figures 1D,G and Data S2). These results suggest that although all 222 SARS-CoV-2-infected individuals can produce RBD-specific Abs, they may not be 223 endowed with enough avidity or are not present at a sufficiently high concentration to 224

block RBD binding to ACE2 effectively. This is illustrated by the large fraction of 225 samples with RBD binding titers ranging between 10 2 to 10 3 and which did not block 226 RBD binding to ACE2 efficiently ( Figure 1H ). We found a positive correlation between 227 the titers of Abs inhibiting RBD binding to ACE2 and neutralizing serum Ab titers (ID80) 228

( Figure 1I) , suggesting that the blockade-of-binding approach could be implemented as 229 a high-throughput, alternative method to measuring serum neutralizing Ab titers, as 230 recently suggested (Tan et al., 2020) . 231

Collectively, these findings indicate that the Ab responses to SARS-CoV-2 S are 232 dominated by anti-RBD Abs and that the majority of the neutralizing activity against 233 SARS-CoV-2 is mediated by RBD-specific Abs interfering with binding to ACE2. 234 235

To characterize persistence of potentially protective Abs, we carried out a 237 longitudinal analysis of IgG titers specific for SARS-CoV-2 antigens at two time points 238

(average of 44 days between samples) in 368 individuals tested within 3 months of 239

infection. RBD-specific IgG titers declined by 35% on average between the two time 240

points tested (Figures 2A-B) , with a monthly average decay of approximately 25%, and 241

this trend was independent of the magnitude of the initial binding titers. We also 242 followed the kinetics of RBD-and N-specific serum IgG over a period of up to 126 days 243 from the collection of the first sample (approximately 150 days after onset of symptoms) 244

for a subset of 24 individuals (Figures 2C). This analysis revealed an average decay of 245 RBD-specific IgGs of 67% over four months (21% per month), consistent with the above 246 finding with a larger cohort. To further characterize the decay kinetics of the RBD-and 247 N-specific IgG following onset of disease symptoms, a longitudinal mixed effects model 248 was employed in a subset of 18 convalescent, hospitalized and symptomatic, 249

individuals who had available data on symptom onset from the start of infection ( Figure  250 2D). The model predicted a half-life of 49 days for RBD-specific IgG Abs and 75 days 251 for S-and N-specific IgG Abs (Figure 2D ), respectively. No significant differences were 252 observed in the decay kinetics in the hospitalized compared to symptomatic individuals. 253

The kinetics of anti-RBD Ab titers blocking attachment to ACE2 did not mirror the 254 overall decay observed for RBD-specific IgG. Indeed, we observed in the same samples 255 an increase in Ab titers blocking attachment to ACE2 for 47% of the individuals who 256 made this type of Abs (which account for 20% of subjects analyzed) (Figures 2E-F) .

This increase, which is not influenced by the initial titer of RBD-specific Abs, might result 258 from the development of Abs with increasingly higher affinity, in the context of an overall 259 J o u r n a l P r e -p r o o f waning of Abs titers targeting the RBD. Indeed, we measured an overall increased 260 avidity of RBD-specific Abs between the two time points tested in support of this 261 hypothesis (Figures 2G-H) .

Although we observed a progressive decay of Ab titers, our results demonstrate 263 a change in the quality of the Ab responses that is expected to result in increased 264

neutralizing activity based on the aforementioned correlation with blocking ACE2 265 attachment.

Structural characterization of the S2H13 RBM-specific neutralizing mAb 268 recognizing multiple RBD conformers 269

Given the heterogeneity of the humoral responses across individuals and the fact 270 the RBD is the prime target of neutralizing Abs, we set out to understand the fine 271 specificity of RBD-targeting Abs elicited in SARS-CoV-2-or SARS-CoV-exposed with the SARS-CoV-2 S ectodomain trimer by cryoEM.

The S2H13 neutralizing mAb was isolated from plasma cells of a SARS-CoV-2 277

infected individual 17 days after disease onset (Figures 3A and S3A Table S1 ). To improve the resolvability of the S2H13 density, 283

which was much lower than most other regions of the map, we used local refinement to 284 determine a reconstruction at ~3.5 Å resolution enabling building the S2H13 variable 285 domains and its epitope ( Figure S4F and S/S2H13 complex reveals that S2H13 and ACE2 would clash upon binding to S and 300 that they share partially overlapping binding sites although they have almost orthogonal 301 orientations relative to the RBD ( Figure 3F ). We confirmed these findings using biolayer 302

interferometry and ELISA to show that S2H13 competes with ACE2 for recognition of 303 the SARS-CoV-2 RBD (Figures 3G and S3D) . Therefore, S2H13 likely neutralizes 304 SARS-CoV-2 by preventing viral attachment to host cells via recognition of an S epitope 305 that remains accessible in both open and closed S states, which is not the case for the 306 ACE2-binding site. 307

Only 6 out of 20 residues within the S2H13 epitope are conserved across SARS-308

CoV to its angle of approach (Figures 4B and 4C) . 339 J o u r n a l P r e -p r o o f S2H14 recognizes an epitope overlapping with the RBM which is inaccessible in 340 the closed S state but becomes exposed upon RBD opening (Figures 4B-4E hydrogen-bonding and shape complementarity ( Figure S6A ).

The structures show that S2H14 and ACE2 bind to largely overlapping sites in 348 the RBM ( Figure 4F ) and would be sterically incompatible with simultaneous binding to 349 a single SARS-CoV-2 RBD ( Figure 4G ). We validated this observation using biolayer 350

interferometry and ELISA to show that S2H14 competed with ACE2 for recognition of 351 the SARS-CoV-2 RBD (Figures 4H and S3D) , indicating that S2H14 likely neutralizes 352 SARS-CoV-2 through inhibition of virus/host cell interaction.

We found that 13 out of 23 epitopes residues are substituted between SARS-354

CoV-2 and SARS-CoV, thereby rationalizing the lack of cross-reactivity of S2H14 with 355 the latter virus ( Figure 4I, Figures S3B and S6 ; Table S2 ). Moreover, SARS-CoV-2 356 variants have already been detected for 15 epitope residues which suggests that some 357 of the viruses currently circulating in humans might be able to escape S2H14-mediated 358 neutralization ( Figure S3F ).

The S2A4 mAb recognizes a cryptic epitope leading to release of the S 1 subunit 361

The S2A4 mAb was isolated from memory B cells of a hospitalized patient 24 362 days after disease onset and was found to weakly neutralize SARS-CoV-2 infection 363 (Figures 5A and S3A Tables S1 and S3). Furthermore, we obtained a low-resolution reconstruction of the S 1 375 subunit trimer bound to three S2A4 Fabs (Figures S7G and S7H ).

S2A4 binds to a cryptic epitope (distinct from the RBM) requiring opening of two 377 adjacent RBDs to be unmasked and allow Fab binding (Figures 5B-5C ). This finding 378

along with the detection of an S 1 subunit trimer class, which we interpret as being 379 J o u r n a l P r e -p r o o f triggered S with a disordered fusion machinery remaining covalently linked ( Figure  380 S3G), suggest that S2A4 acts as a molecular ratchet biasing the SARS-CoV-2 S 381 conformational equilibrium towards opened RBDs. We confirmed these results by 382

showing that S2A4 promoted shedding of the S 1 subunit from cell-surface expressed 383

full-length wild-type S, as was the case with the RBM-targeted S2H14 ( Figure S3E ).

Our data are also in line with previous reports of the SARS-CoV neutralizing mAb S230- S2A4 binding to the RBD buries an average surface of ~850Å 2 using all six CDR 391 loops along with contributions from FRH3 and FRL3. CDRH3 and CDRL1 dominate the 392 interface which involve electrostatic and hydrophobic interactions (Figures 5D and 5E ).

The S2A4 epitope comprises residues 368-388, which form two α-helices and an 394

intervening β-strand participating in the formation of the structurally conserved RBD β-395

sheet, and residues 407-414 forming an α-helix followed by a loop segment (Figures 396 5D-5E and Figure S6A ).

S2A4 recognizes an epitope distinct from the RBM and its footprint does not 398

overlap with the ACE2-binding site ( Figure 5F ). However, our cryoEM structure 399

indicates that upon binding S2A4 would sterically clash with ACE2 interacting with the 400 same protomer within an S trimer. We used biolayer interferometry and ELISA to 401

validate these structural findings and demonstrated that S2A4 and ACE2 compete for 402

binding to the SARS-CoV-2 RBD indicating that the neutralizing activity of this Ab likely 403 results from preventing viral attachment to its host cell receptor (Figures 5G and S3D ).

Sixteen out of 19 epitope residues are conserved across SARS-CoV-2 and 405 SARS-CoV S glycoproteins (Figures 5H, S6A and S3F; Table S1 ). Furthermore, we obtained a 10Å resolution cryoEM 424 reconstruction of the S 1 subunit trimer with 3 bound S304 Fabs (Figures 6C, S7N-S7O) .

S304 recognizes a cryptic epitope, which is buried in the closed S conformation 426 but is distinct from the RBM, with one S304 Fab bound to each of the three open RBDs 427

( Figures 6A-6B ). CDRH1-H3, CDRL1 and CDRL3 interact with SARS-CoV-2 S through 428

burial of an average surface area of 900Å 2 at the epitope/paratope interface involving 429 electrostatic interactions and shape complementarity ( Figure 6D ). Based on the crystal 430 structure of the RBD/S304/S309/S2H14 complex, the S304 epitope comprises residues 431 366-392, which form two α-helices and an intervening β-strand, as well as residues 515-432 517 (both regions participating in the formation of the structurally conserved RBD β-433

sheet), and loop residues 411-414 and 427-430 ( Figure 6D , Figure S6A and Table  434 S3). Although S304 binds away from the RBM, we observed partial competition 435 between S304 and ACE2 for binding to the SARS-CoV-2 RBD which might be 436 explained by steric hindrance with the ACE2 N322 glycan and/or with the ACE2 N-437 terminus (through the heavy chain constant domain of S304 bound to a neighboring 438 protomer) ( Figures 6E and S3D ). 439

Cross-reactivity of S304 with SARS-CoV-2 S and SARS-CoV S is explained by 440

the conservation of 23 out of 25 epitope residues with neither of the two substitutions 441

(P SARS-CoV-2 384A SARS-CoV and T SARS-CoV-2 430M SARS-CoV ) predicted to affect binding in light 442 of our structural data Figures 6F, S3B and S6A). The conserved nature of the S304 443 epitope among sarbecoviruses indicate that S304 is likely to cross-react with other 444 related sarbecoviruses (Figures S3F, S6B and Table S2 ).

The S304 epitope partially overlaps with the epitopes of the weakly neutralizing These epitopes are SARS-CoV-2-specific and harbor several naturally occurring 490 mutations among circulating viral isolates ( Figure S3F and Table S2 ). The S2X35, 491

S2A4 and S304 mAbs recognize overlapping cryptic epitopes, that are only accessible 492 when at least two RBDs are open, respectively termed sites IIa, IIb and IIc, which are 493 positioned increasingly further away from the ACE2-binding site (Figures 7D-7F ). 494

Finally, S309 binds to a conserved epitope termed site IV, which is accessible 495

independently of the RBD conformation, and neutralizes SARS-CoV-2 without 496

interfering with ACE2 binding (Figure 7G ) (Pinto et al., 2020) .

S309 and S2H13 are set apart from the other mAbs studied here as they 498

recognize epitopes accessible in both the closed and open S states. Consistent with a 499 recent report that the closed S state is favored at endosomal pH (Zhou et al., 2020b) , 500

we found that binding of all mAbs to the S ectodomain was dampened at pH 5.4, except 501

for S309 and S2H13, whereas binding of all these mAbs to the free RBD was not 502

affected at pH 5.4 (Figures S5A and S5B ). S309 and S2H13 do not select for a specific 503 S conformation nor promote S 1 shedding, which are specific features of site Ia-and site 504

II-targeted mAbs ( Figure S3E ). Based on these data, we hypothesize that high-density 505

binding of S309 or S2H13 to multiple S conformations may explain their unique ability to 506

trigger Fc-mediated effector functions efficiently among the panel of mAbs tested. 507

To characterize the fine specificity of Ab responses to the RBD in SARS-CoV-2 508

infected individuals, we developed a quantitative blockade-of-binding assay using the 6 509 structurally defined mAbs as probes for the corresponding antigenic sites (Figures 7B-510 7G). Abs against sites Ia and Ib were found at high titers in hospitalized donors and in a 511

fraction of non-hospitalized symptomatic and asymptomatic subjects, and correlated 512

with the titer of Abs blocking binding of the RBD to ACE2 (Figures 7H-7K) . The 513

serological response to the other RBD antigenic sites was overall lower (or null) but 514

showed distinct signatures in different individuals. In particular, we did not detect Abs to 515

any RBD sites in 22% of non-hospitalized individuals. Although we cannot rule out the 516 possible existence of additional antigenic sites, the most plausible explanation is that 517 these individuals possess low level of RBD-specific Abs (Figures 7K-7L) , putatively 518

with low avidity, compounding their detection in the blockade-of-binding assay. In 519 addition, the overall waning of the total anti-RBD Abs was paralleled by a similar decay 520

of Abs directed to each RBD site (Data S4). Collectively, our results demonstrate that 521

the SARS-CoV-2 RBD is the main target of neutralizing Abs and that sites Ia and Ib are 522 prime antigenic sites.

This study provides an extensive analysis of Ab responses to SARS-CoV-2 S, 526 RBD and N in more than 600 SARS-CoV-2 infected individuals with different clinical 527

outcomes. Collectively, our data define the immunodominance of the RBD and highlight 528 qualitative and quantitative differences in the serological response of different 529

individuals. The SARS-CoV-2 RBD is immunodominant in terms of total Abs elicited and 530

is the target of 90% of the neutralizing activity present in the sera or plasma of most immune status, co-morbidities or antigenic load. 556

We observed waning of IgG titers to RBD with an approximate half-life of 49 days 557

in the individuals that we could follow for a period of approximately 4 months, a finding 558 that is consistent with a recent study (Seow et al., 2020) . The half-life determined in our 559 study is longer than the average IgG half-life, which is about 20 days, indicating 560

sustained Ab production by short-lived or long-lived plasma cells. If stable, this kinetics 561 of decay would lead to a potential 99% reduction of RBD-specific IgG titers a year after 562

infection, although a more precise determination of the long-term decay will require 563

follow-up studies. However, the overall decay of RBD-specific Abs was accompanied by 564 an increase in Ab titers blocking ACE2 binding in several individuals and by an increase 565

in the avidity of RBD-specific IgG Abs, consistent with an ongoing affinity maturation of 566 the antibody response to SARS-CoV-2 spike. These findings highlight the importance of 567 using both binding and functional assays to evaluate the Ab responses induced by 568

vaccines.

The abundant IgG and IgA responses to SARS-CoV-2 N is reminiscent of the Ab 570 responses to other internal viral proteins such as p24 in HIV-1 and HBcAg in HBV and 571 is most likely due to the abundant release of N protein from killed infected cells and/or 572 disassembled virions (Gimson et al., 1983; Lindhardt et al., 1989) . The lack of 573 detectable IgM responses to N is a surprising finding and may be related to either 574 activation of a cross-reactive memory response to coronavirus N proteins or rapid class-575 switching due to the highly stimulatory capacity of antigens that are associated with 576 RNA, which is a strong TLR7 agonist (Lund et al., 2004 ). 577

We used information gained from 6 different mAb structures to develop a high-578 resolution serological epitope-mapping approach and define a blueprint of polyclonal Ab 579 J o u r n a l P r e -p r o o f responses to the SARS-CoV-2 RBD. These data present a quantitative antigenic map of 580 the epitopes targeted by neutralizing mAbs that explains immunodominance, 581

neutralization properties and activation of effector functions. We found that the RBM is 582

immunodominant and comprises two partially overlapping antigenic sites (Ia and Ib 583 defined by mAbs S2H14 and S2H13, respectively) targeted by neutralizing Abs 584

inhibiting ACE2 attachment. Whereas site Ia coincides with the ACE2 binding site and is 585 accessible only in the open S conformation, site Ib is also exposed in the closed S 586 conformation and is targeted by Abs with both neutralizing activity and effector function. 587

In contrast, the remaining RBD sites, IIa, IIb, IIc and IV, are subdominant and generate 588

lower and variable Ab responses in different individuals. The immunodominance of sites 589

Ia and Ib may be related to their greater accessibility compared to sites IIa, IIb and IIc, 590

as the latter epitopes become exposed only after opening of two RBDs, which is a rare These findings imply that extensive somatic hypermutation is not necessary to achieve 628 neutralization of SARS-CoV-2 and other coronaviruses and that similar Abs might be 629 easily elicited through vaccination. Given the immunodominance of the RBD for the 630 elicitation of neutralizing Abs, we suggest that SARS-CoV-2 RBD-based immunogens, 631

potentially engineered for multivalency, bear the promise of eliciting potent neutralizing 632

Ab responses and represent an attractive target for rational vaccine design. structure. We would like to thank Marcel Meury for assistance with protein production 648

and Josh Dillen and Cindy Ng for assistance with protein production and crystallization. 649

We acknowledge Tatiana on the sensor chip surface and binding at multiple mAb concentrations was measured. 866

Neutral pH measurements were performed in multi-cycle format (A) and acidic pH 867 measurements in single-cycle format (B). All data have been fit to a 1:1 binding model, 868

which is an approximation for the S-binding data, since the kinetics incorporate 869

conformational dynamics between open and closed RBD states, and because IgG 870

binding involves avidity. protomer is colored distinctly (cyan, pink and gold 

Further information and requests for resources and reagents should be directed 926 to and will be fulfilled by the Lead Contact, David Veesler (dveesler@uw.edu). 927

Materials generated in this study will be made available on request and may 929 require a material transfer agreement. 930

The cryo-EM maps and atomic models have been deposited at the Electron 932

Microscopy Data Bank and the PDB with accession codes listed in Tables S1 and S3. Cell lines used in this study were obtained from ATCC (HEK293T, Vero-E6), 938

Thermo-Fisher Scientific (HEK293F, Expi293F) or Invitrogen (Expi-CHO-S cells). All cell 939 lines used in this study (except HEK293F and Expi293F) were routinely tested for 940 mycoplasma and found to be mycoplasma-free. 941

Samples were obtained from 5 cohorts of SARS- symptoms of a-f and any of g-j), mild symptomatic (any 3 symptoms of a-f); high 955 symptomatic (any 4 symptoms of a-f), severe symptomatic (any 4 symptoms of a-f, 956

including b), atypical (all the remaining cases). 957

PBMCs and plasma were isolated from blood draw performed using tubes or 961 syringes pre-filled with heparin, followed by Ficoll density gradient centrifugation. Sera 962

were obtained from blood collected using tubes containing clot activator, followed by 963 centrifugation. PBMCs, plasma and sera were stored in liquid nitrogen and -80°C 964 freezers until use, respectively. 965 each other across each acidic pH dataset. Double reference-subtracted data were fit to 1218 a 1:1 binding model using Biacore Evaluation software, which yields an "apparent K D " 1219

for the S-binding data because the kinetics also reflect S conformational dynamics and 1220 especially for the IgG binding data where the kinetics also reflect avidity. RBD-binding 1221 data were fit with a Global Rmax. Spike-binding data for the tightly-associating S309 1222

and S2X35 Fabs as well as all IgG measurements were fit with local Rmax, due to the S 1223 conformational changes which can affect the accessibility of epitopes across different 1224 mAb concentrations (these K D,app are indicated to be approximate). For dissociation 1225

rates that were too slow to fit, K D,app are reported as an upper limit. 1226

The SARS-CoV-2 RBD was loaded for 3 min at 8 µg/ml in kinetics buffer onto 1229

anti-Penta-HIS (HIS1K) biosensors (Molecular Devices, ForteBio). Association of mAbs 1230

(full-length IgG) was performed in kinetics buffer (0.01% endotoxin-free BSA, 0.002% 1231

Tween-20, 0.005% NaN3 in PBS) at 15 µg/ml for 7 min. 1232 1233 1234

Crystallization, data collection, structure determination and analysis 1235

Crystals of the SARS-CoV-2 RBD-S304-S309- S2H14 before performing another round of non-uniform refinement in cryoSPARC followed by 1319

per-particle defocus refinement and again non-uniform refinement. 1320

To further improve the density of the S2H13, S2A4 and S2X35 Fabs, the 1321 particles were symmetry-expanded and subjected to focus 3D classification without 1322 refining angles and shifts using a soft mask encompassing the RBM and S2H13 1323 variable domains or RBD and S2A4 or S2X35 variable domains using a tau value of 60 1324 (S2H13 and S2A4) or 40 (S2X35). Particles belonging to classes with the best resolved 1325

Fab density were selected (all particles were retained for S2X35) and subjected to local 

SEC fractions corresponding to the main protein peak were pooled, flash frozen in liquid 1012 nitrogen and stored at -80°C

which encodes for an N-terminal mu-phosphatase signal 1015 peptide, an 'ETGT' linker, SARS-CoV-2 residues 328-531, a linker sequence and Strep-1016 8xHis-tag. Supernatants were harvested five days after transfection

which encodes for an N-terminal mu-phosphatase 1023 signal peptide, an 'ETGT' linker, SARS-CoV-2 residues 328-531 and a C-terminal 1024 8xHis-tag. Protein was expressed in Expi293F cells in the presence of 10 µM 1025 kifunensine at 37°C and 8% CO 2 in a humidified incubator. Transfection was performed 1026 using ExpiFectamine 293 reagent (Thermo Fisher Scientific) and 1 µg plasmid per ml of 1027 cell culture. Cell culture supernatant was collected after three days and supplemented 1028 with EDTA-free Protease Inhibitor (Thermo Scientific Pierce) and PBS to a final 1029 concentration of 2

CoV-2 RBD was purified using a 5 ml HisTALON Superflow cartridge (Takara Bio) and 1031 subsequently dialyzed against 50 mM Tris-HCl pH 7.5, 150 mM NaCl. SARS-CoV-2 1032 RBD was deglycosylated by overnight incubation with EndoH glycosidase at 4°C

RBD (residues 328-531) with a C-terminal Thrombin-1034 Twin-Strep-8xHis-tag was expressed in Expi293F cells at 37°C and 8% CO2 in a 1035 humidified incubator. Transfection was performed using ExpiFectamine 293 reagent 1036 (Thermo Fisher Scientific) and 1 µg plasmid per ml of cell culture. The protein was 1037 purified by affinity chromatography using a 1 ml HisTALON Superflow cartridge as 1038 described above (Takara Bio) and subsequently buffer exchanged using a Zeba

To form the quaternary SARS-CoV-2 RBD-S304-S309-S2H14 Fab complex, the 1042 deglycosylated SARS-CoV-2 RBD was mixed with a 1.3-fold molar excess of S304 Fab, 1043 S309 Fab and S2H14 Fab

Polyvalan Crystallophore N°1 and this solution was used for setting up crystallization 1047 trays

Recombinant ACE2 was expressed in ExpiCHO-S cells transiently transfected 1049 with a plasmid encoding ACE2 residues 19-615, a C-terminal thrombin cleavage site, 1050 Twin-Strep-tag and 10xHis-tag. Cell culture supernatant was collected nine days after 1051 from the same crystal processed with the XDS software package (Kabsch, 2010), were 1243 merged for a final dataset at 2.65 Å in space group C2

Using the 1249 RBD-S304-S309-S2H14 Fab complex crystal structure, the S309, S304 and S2H14 1250 binding epitopes on the RBD protein were determined by identifying all RBD residues 1251 within a 5.0Å distance from any Fab atoms. The analysis was performed using the 1252 Molecular Operating Environment (MOE)

A total of 150 nl of 1256 Fabs at 20 mg per mL (for S2H14 and S2A4) or at 12 mg per mL (for S2X35

Drops were equilibrated against reservoir solutions for 1-2 weeks at room 1262 temperature after which crystals were flash cooled in liquid nitrogen using the mother 1263 liquor solution supplemented with 30% glycerol as a cryoprotectant. Diffraction data 1264 were remotely recorded on synchrotron beamline 5.0.2 at ALS, indexed and scaled 1265 using Mosfilm (Battye et al., 2011) and SCALA or aimless (Evans and Murshudov

CryoEM sample preparation, data collection and data processing

S2H13 Fab was generated by digestion of the corresponding monoclonal IgG 1273 with LysC (Thermo Fisher Scientific) at 1:2000 (w/w) ratio during 5 h at 37°C while Fabs 1274 S2A4, S2H14, S304 and S2X35 were recombinantly expressed as described above

SARS-CoV-2 S at 1.2 mg per mL was incubated with 1.2 molar excess of Fabs at 4°C 1276 at least for 1 h. Three µL of 1-1.5 mg per mL of complexes was loaded onto a freshly 1277 glow discharged 1.2/1.3 UltrAuFoil grid (300 mesh) prior to plunge freezing using a 1278 vitrobot MarkIV

The dose rate was adjusted to 8 1286 counts/pixel/s, and each movie was fractionated in 50 frames of 200 ms. For the S/S304 1287 dataset, 2,791 micrographs were collected with a defocus range comprised between -1288 1.5 and -2.8 µm. For the S/S2H13 data set

Movie frame alignment, estimation of the microscope contrast-transfer function 1292 parameters, particle picking and extraction were carried out using Warp

Particle images were extracted with a box size of 800 binned to 400 1294 yielding a pixel size of 1.05 Å

at a nominal magnification of 36,000x 1298 with a pixel size of 1.16 Å and stage tilt angle of 40˚ or 30˚ for S/S2H14 or S/S2X35 1299 complexes, respectively

2019) was also used for movie frame alignment, 1305 estimation of the microscope contrast-transfer function parameters, particle picking and 1306 extraction

2017) 1309 to select well-defined particle images (only one round of reference-free 2D classification 1310 was performed for S/S2X35). Subsequently, two rounds of 3D classification with 50 1311 iterations each (angular sampling 7.5˚ for 25 iterations and 1.8˚ with local search for 25 1312 iterations), using our previously reported closed SARS-CoV-2 S structure as initial 1313 model (PDB 6VXX) or ab initio generated models for S2H14, S304 or S2X35 (Punjani et 1314 al., 2017), were carried out using Relion (Scheres, 2012b) without imposing symmetry. 1315 3D refinements were carried out using non-uniform refinement along with per-particle 1316 defocus refinement in cryoSPARC

Privateer: software for the conformational validation of carbohydrate structures

Antibody Response and Disease Severity 1413 in Healthcare Worker MERS Survivors

A Potently Neutralizing Antibody Protects Mice against SARS-1416 CoV-2 Infection

EMRinger: side chain-directed model and map validation for 3D cryo-electron microscopy

Structures of Human

Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of 1423 Antibodies

iMOSFLM: a 1425 new graphical interface for diffraction-image processing with MOSFLM

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid 1429 mutational escape seen with individual antibodies

Potent neutralizing antibodies from 1432 COVID-19 patients define multiple targets of vulnerability

Effect of specific humoral immunity and some non-specific factors on 1434 resistance of volunteers to respiratory coronavirus infection

The time course of the immune 1436 response to experimental coronavirus infection of man

Disappearance of 1438 antibodies to SARS-associated coronavirus after recovery

One number does not fit all: mapping local 1440 variations in resolution in cryo-EM reconstructions

High-resolution noise substitution to measure overfitting and validate 1443 resolution in 3D structure determination by single particle electron cryomicroscopy

MolProbity: all-atom structure validation for 1447 macromolecular crystallography

A neutralizing antibody selected from plasma cells that 1453 binds to group 1 and group 2 influenza A hemagglutinins

Prophylactic and postexposure efficacy of a 1456 potent human monoclonal antibody against MERS coronavirus

Prophylactic efficacy of a human monoclonal antibody 1460 against MERS-CoV in the common marmoset

Broadly neutralizing anti-influenza 1462 antibodies require Fc receptor engagement for in vivo protection

Differential Fc-Receptor Engagement Drives an Anti-tumor 1464 Vaccinal Effect

Broadly neutralizing hemagglutinin 1466 stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo

Transmission of MERS-coronavirus in 1470 household contacts

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Coronavirus protective immunity is short-lasting

Data, disease and diplomacy: GISAID's innovative 1478 contribution to global health

Features and development of Coot

How good are my data and what is the resolution? 1482

Safety and immunogenicity of the ChAdOx1 1485 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, 1486 randomised controlled trial

Automatically Fixing Errors in Glycoprotein Structures with Rosetta

Serological 1491 markers in fulminant hepatitis B

UCSF ChimeraX: Meeting modern challenges in visualization and analysis

Targets of T Cell Responses to SARS-CoV-1497 2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Long-Term 1500 Persistence of IgG Antibodies in SARS-CoV Infected Healthcare Workers. medRxiv

Alveolar macrophages are critical for 1504 broadly-reactive antibody-mediated protection against influenza A virus in mice

Hemagglutinin receptor binding 1508 avidity drives influenza A virus antigenic drift

Fc receptor but not complement 1511 binding is important in antibody protection against HIV

A Multibasic Cleavage Site in the 1513

Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells

SARS-CoV-2 Cell Entry Depends on ACE2 1517 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Neutralisation of SARS-CoV-2 by destruction of the 1520 prefusion Spike

3B11-N, a monoclonal antibody against MERS-CoV, reduces 1523 lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-1524 n3/2012

A Cryptic Site of Vulnerability on the Receptor Binding 1527 Domain of the SARS-CoV-2 Spike Glycoprotein. bioRxiv

Potent human neutralizing antibodies elicited by SARS-CoV-2 infection. bioRxiv

Structures and distributions of SARS-CoV-2 spike proteins on intact 1534 virions

Stabilized coronavirus spikes are resistant 1537 to conformational changes induced by receptor recognition or proteolysis

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 1540 receptor

Attenuated SARS-CoV-2 variants with deletions at the S1/S2 junction

Functional assessment of cell entry and receptor 1545 usage for SARS-CoV-2 and other lineage B betacoronaviruses

Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients 1548 With Severe and Life-threatening COVID-19: A Randomized Clinical Trial

The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity

Macromolecular structure determination using X-rays, 1553 neutrons and electrons: recent developments in Phenix

Antibodies against the major core protein p24 of human immunodeficiency virus: 1557 relation to immunological, clinical and prognostic findings

Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 1561 spike

Convalescent plasma treatment of 1564 severe COVID-19: A matched control study. medRxiv

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Serological Analysis of New York City 1570 COVID19 Convalescent Plasma Donors. medRxiv

Recognition of single-stranded RNA viruses by Toll-like receptor 7

Phaser crystallographic software

SARS-like WIV1-CoV poised for 1578 human emergence

Host cell proteases: Critical determinants of coronavirus 1580 tropism and pathogenesis

REFMAC5 for the refinement of macromolecular crystal 1583 structures

Pre-existing and <em>de novo</em> humoral immunity to 1586 SARS-CoV-2 in humans. bioRxiv

Elucidating the interplay between IgG-Fc 1589 valency and FcγR activation for the design of immune complex inhibitors

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-1593 reactivity with SARS-CoV

Immunogenicity and structures of a rationally 1596 designed prefusion MERS-CoV spike antigen

UCSF Chimera--a visualization system for exploratory research and analysis

Cross-neutralization of SARS-CoV-2 by a human 1602 monoclonal SARS-CoV antibody

Cross-sectional evaluation of humoral 1605 responses against SARS-CoV-2 Spike

cryoSPARC: algorithms for 1607 rapid unsupervised cryo-EM structure determination

Non-uniform refinement: Adaptive regularization 1609 improves single particle cryo-EM reconstruction. bioRxiv

Convergent antibody responses to SARS-CoV-2 in 1612 convalescent individuals

Structural basis for potent cross-neutralizing human monoclonal antibody protection 1615 against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection 1619 from disease in a small animal model

A Bayesian view on cryo-EM structure determination

RELION: implementation of a Bayesian approach to cryo-EM structure 1623 determination

Longitudinal evaluation and decline of antibody 1626 responses in SARS-CoV-2 infection. medRxiv

Characterization of neutralizing antibodies 1629 from a SARS-CoV-2 infected individual. bioRxiv

Structural basis of receptor recognition by SARS-CoV-2

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Cryo-EM structure of the SARS coronavirus 1635 spike glycoprotein in complex with its host cell receptor ACE2

Specificity, cross-reactivity, and function of 1638 antibodies elicited by Zika virus infection

Automated molecular microscopy: the new Leginon system

A SARS-CoV-2 surrogate virus neutralization test based on antibody-1644 mediated blockage of ACE2-spike protein-protein interaction

A potent broadly neutralizing human RSV antibody targets conserved 1650 site IV of the fusion glycoprotein

Real-time cryo-electron microscopy data preprocessing 1652 with Warp

Human monoclonal antibody 1655 combination against SARS coronavirus: synergy and coverage of escape mutants

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human 1659 monoclonal antibody

Structural insights into coronavirus entry

An efficient method to make human monoclonal 1664 antibodies from memory B cells: potent neutralization of SARS coronavirus

In situ structural analysis of SARS-CoV-2 spike 1668 reveals flexibility mediated by three hinges

Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Cryo-electron microscopy structure of a coronavirus spike glycoprotein 1673 trimer

Glycan shield and epitope masking of a coronavirus spike protein observed 1676 by cryo-electron microscopy

Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane 1679 fusion

Unexpected Receptor Functional Mimicry Elucidates 1682 Activation of Coronavirus Fusion

A human monoclonal 1685 antibody blocking SARS-CoV-2 infection. bioRxiv

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

Automated 1690 structure refinement of macromolecular assemblies from cryo-EM maps using Rosetta

Site-specific glycan 1692 analysis of the SARS-CoV-2 spike

Broad neutralization of SARS-related viruses by 1695 human monoclonal antibodies

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

A 1700 noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its 1701 receptor ACE2

Structural basis for the recognition 1703 of SARS-CoV-2 by full-length human ACE2

Junctional and allele-specific residues are critical for MERS-CoV neutralization 1706 by an exceptionally potent germline-like antibody

A 1708 highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV

Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic 1712 receptor binding domains

A pneumonia outbreak associated with a new coronavirus of probable bat origin

A pH-dependent switch mediates conformational 1718 masking of SARS-CoV-2 spike

New tools for automated high-resolution cryo-EM structure

A Bayesian approach to beam-induced 1723 motion correction in cryo-EM single-particle analysis

8.0, 100 mM NaCl, and then incubated with BioLock solution for one hour. After filtration 1053 through a 0.22 µm filter, ACE2 was purified using a 1 ml StrepTrap High Performance 1054 column (Cytiva) followed by size exclusion chromatography using a Superdex 200 1055Increase 10/300 GL column pre-equilibrated in 20 mM Tris-HCl pH 7.5, 150 mM NaCl. 1056 1057Enzyme-linked immunosorbent assay (ELISA) 1058Spectraplate-384 with high protein binding treatment (custom made from Perkin 1059Elmer) were coated overnight at 4°C with 1 µg/ml of SARS-CoV-2 S, domain A (in-1060 house produced), N (The Native Antigen company), S2 (The Native Antigen company), 1061SARS-CoV S (in-house produced) or 5 µg/ml of SARS-CoV-2/SARS-CoV RBD (in-1062 house produced) in PBS, pH 7.2, and plates were subsequently blocked with Blocker 1063Casein (1%) in PBS (Thermo Fisher Scientific) supplemeted with 0.05% Tween 20 1064(Sigma Aldrich). The coated plates were incubated with serial dilutions of human mAbs 1065 or human plasma or sera for 1 h at room temperature. The plates were then washed 1066with PBS containing 0.1 % Tween-20 (PBS-T), and Alkaline Phosphatase-conjugated 1067Goat Anti-Human IgG, IgM or IgA (Southern Biotech) were added and incubated for 1 1068 h. Plates were washed three times with PBS-T, and 4-NitroPhenyl Phosphate (pNPP, 1069Sigma-Aldrich) substrate was added and incubated for 1 h (IgG) or 2 h (IgA and IgM) .

The absorbance of 405 nm was measured by a microplate reader (Biotek), and the data 1071was plotted with Graph Prism software.

In the depletion experiments, the efficiency was calculated based on the ratio of 1073 the binding titers before and after depletion and is expressed as a percentage: (1-1074 (ED50(after)/ED50(before))*100.

For chaotropic ELISA, after incubation with sera, plates were washed and 1076 incubated with 1 M solution of sodium thiocyanate (NaSCN) for 1 h. Avidity Index was 1077 calculated as the ratio (%) between the ED50 in presence and the ED50 in absence of 1078NaSCN.

Depletion of RBD-specific Abs from plasma or serum samples 1081Magnetic beads (Pierce) were washed with ice-cold 1 mM HCl solution. 1 mg/ml 1082 RBD solution was coupled to magnetic beads in 50 mM borate buffer, pH 8.5, with a 2h 1083 incubation at room temperature. Beads were washed 3 times with 0.1 M glycine, pH 2.0, 1084followed by a wash with purified water. Beads were then incubated with quenching 1085 buffer (3 M ethanolammine, pH 9.0) for 2 h. Beads were washed with purified water and 1086 resuspended in storage buffer (50 mM borate buffer, pH 8.5, with 0.05% sodium azide). 1087Serum or plasma were diluted to 1/50 in 500 µl PBS containing 1/20 (25 µl) of RBD-1088 magnetic beads and incubated for 1 h at room temperature with continuous rotation. 1089Tubes were placed on a magnetic holder and supernatants were collected. 1090 1091

VSV-based SARS-CoV-2 S-glycoprotein-pseudotyped viruses were used to test 1093 the neutralizing activity of serum or plasma from COVID-19 recovered patients. Briefly, 1094HEK293T cells were transfected with a SARS-CoV-2 S glycoprotein-encoding plasmid 1095harboring the ∆19 C-terminal truncation (Ou et al., 2020) using the X-tremeGENE HP 1096DNA transfection reagent (Merk) according to the manufacturer's instructions and then 1097 incubated at 37 °C with 8% CO 2 for 24 h. Next, the transfected cells were infected with 1098Delta-G-VSV-Luc in DMEM and incubated 1h at 37 °C with 5% CO 2 . After removing the 1099 infection medium, the cells were washed twice with PBS and DMEM containing 10% 1100FBS and 1% penicillin-streptomycin was added. Infected cells were further incubated 1101for 24 hours at 37°C before the supernatant containing the VSV-SARS-CoV-2 1102 pseudoviruses was collected, cleaned from cellular debris by centrifugation, and stored 1103at -80°C. VSV-SARS-CoV-2 pseudovirus was incubated with serial dilution of serum or 1104 plasma for 1 h in white culture 96 well plate at 37°C. Next, VeroE6 at 20 000 cells/well 1105 were added to the mix and incubated 2 h at 37°C. After 2 h, MEM supplemented with 1106 40% FBS and 4% penicillin-streptomycin was added to the cells for additional 24h. 1107Culture medium was then removed from the cells and 50 µL/well of Bio-Glo (Promega) 1108diluted 1:2 with PBS Ca 2+ Mg 2+ was added. After 5 minutes incubation in the dark, the 1109 luminescence signal was measured using a Synergy H1 Hybrid Multi-Mode plate reader 1110(Biotek). Measurements were performed in duplicate and relative luciferase units (RLU) 1111were converted into neutralization percentages and plotted with a nonlinear regression 1112 curve fit in Graph Prism. 1113In the depletion experiments, the efficiency was calculated based on the ratio of 1114 the neutralizing titers before and after depletion and is expressed as a percentage: (1-1115 (ID80(after)/ID80(before))*100. 1116MLV-based SARS-CoV-2 S-pseudotyped viruses were used to test the 1117 neutralizing activity of recombinant mAbs, as previously described (Walls et al., 2020) .

HEK293T cells were co-transfected with a SARS- 

Human anti-RBD full IgG1 mAbs were biotinylated using the EZ-Link NHS-PEO 1144 solid phase biotinylation kit (Pierce). Labelled mAbs were tested for binding to RBD by 1145ELISA and the optimal concentration of each mAb to achieve 80% maximal binding was 1146 determined. Unlabeled mAbs or sera/plasma were serially diluted and added to ELISA RBDs open. Each SARS-CoV-2 protomer is colored distinctly (cyan, pink and gold). The 1392S2A4 light and heavy chains are colored magenta and purple, respectively. H-I. CryoEM 1393 reconstruction of the S 1 subunit trimer (with disordered S 2 ) bound to three S2X35 Fabs 1394 viewed along two orthogonal orientations and the corresponding atomic model fit in 1395